Journal list menu
IssueCancer Communications: Volume 43, Issue 3
295-412March 2023
Export Citations
Download PDFs
ISSUE INFORMATION
REVIEW
Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions
- Pages: 297-337
- First Published: 10 November 2022
ORIGINAL ARTICLES
METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression
- Pages: 338-364
- First Published: 05 January 2023
μ-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial
- Pages: 365-386
- First Published: 05 February 2023
RESEARCH HIGHLIGHT
Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 2
- Pages: 387-390
- First Published: 05 January 2023
LETTERS TO THE EDITOR
Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: a prospective study
- Pages: 391-394
- First Published: 03 February 2023
Novel endogenous endoplasmic reticulum transmembrane protein SURF4 suppresses cell death by negatively regulating the STING-STAT6 axis in myeloid leukemia
- Pages: 395-399
- First Published: 06 November 2022
C-terminal variants of the P2X7 receptor are associated with prostate cancer progression and bone metastasis – evidence from clinical and pre-clinical data
- Pages: 400-404
- First Published: 29 December 2022
Activation mechanisms of clinically distinct B-Raf V600E and V600K mutants
- Pages: 405-408
- First Published: 26 December 2022
Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection
- Pages: 409-412
- First Published: 24 December 2022
Sign up for email alerts
Tools
More from this journal
Cancer collection based on different tumor types
Information for Authors
Cancer Communications offers waivers to authors for selected high quality articles. For rapid feedback on the potential suitability of an article for waiver, please send a pre-submission enquiry to the editorial office, providing the article title, abstract and a brief cover letter.
Impact Factors in Journal Citation Report (2018, Clarivate) are under the previous journal title Chinese Journal of Cancer.
Archival Content
To browse articles published in the journal prior to March 2015, please visit the Sun Yat-sen University Cancer Center website.
Understanding Open Access
As an open access journal, all articles in Cancer Communications are freely available to read, download and share immediately on publication.
Relevant Open – Access Health Sciences journals
Aging AND Cancer (2020-Present)
Cancer Innovation (2022-Present)
Clinical and Translational Medicine (2012-Present)
MedComm (2020-Present)
MedComm – Oncology (2022-Present)